Dual therapy non inferior to triple therapy in AF after PCI

A new study looking at a dual antithrombotic strategy in patients with atrial fibrillation after PCI has bolstered evidence supporting a move away from standard triple therapy with warfarin. The RE-DUAL PCI study presented at the ESC this week and simultaneously published in the NEJM showed that combining one of two dabigatran (Pradaxa) doses with ...

Already a member?

Login to keep reading.

© 2021 the limbic